title: Selenium nanoparticles inhibit the growth of HeLa and MDA-MB-231 cells through induction of S phase arrest.
abstract: In vitro antiproliferative effects of selenium nanoparticles (nanoSe(0), 10-40 μmol/L) on HeLa (human cervical carcinoma) cells and MDA-MB-231 (human breast carcinoma) cells were examined by optical microscopic inspection and MTT assay in the present study. The nanoSe(0) effectively inhibited the growth of MDA-MB-231 cells and HeLa cells in a dose-dependent manner. The morphology analysis with atomic force microscope showed that the HeLa cells treated with 10 μmol/L nanoSe(0) were rough and shrunken with truncated lamellipodia at terminal part of the cells. Flow cytometric analysis demonstrated that HeLa cells were arrested at S phase of the cell cycle after exposed to nanoSe(0) (10 μmol/L). Taken together, our results suggested that nanoSe(0) may be more helpful in cancer chemoprevention as a potential anticancer drug.
authors.affiliation: College of Life Science and Technology, Jinan University, Guangzhou 510632, PR China.
authors.forename: Haiying
authors.initials: H
authors.lastname: Luo
authors.forename: Feifei
authors.initials: F
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Bai
authors.forename: Tianfeng
authors.initials: T
authors.lastname: Chen
authors.forename: Wenjie
authors.initials: W
authors.lastname: Zheng
mesh_terms: D016588:Anticarcinogenic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001205:Ascorbic Acid / Q000737:chemistry / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005434:Flow Cytometry; D006367:HeLa Cells; D006801:Humans; D018625:Microscopy, Atomic Force; D053758:Nanoparticles / Q000737:chemistry*; D016196:S Phase / Q000187:drug effects*; D018036:Selenium Compounds / Q000737:chemistry / Q000494:pharmacology*; D064588:Selenium Oxides; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D016588:Anticarcinogenic Agents; D018036:Selenium Compounds; D064588:Selenium Oxides; D001205:Ascorbic Acid